Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021

More articles from Medical Grand Rounds

  • You have access
    Thalidomide’s tightly controlled “comeback”
    Leonard H. Calabrese, DO
    Cleveland Clinic Journal of Medicine March 1999, 66 (3) 136-138;

    A drug that was banned 40 years ago because of its potential for causing serious birth defects has found new uses—with strict safeguards.

  • You have access
    Beta2-microglobulin amyloidosis in renal failure: Understanding this recently recognized condition
    Jonathan Kay, MD
    Cleveland Clinic Journal of Medicine March 1999, 66 (3) 145-147;

    Most long-term dialysis patients eventually acquire amyloid deposits, with resultant musculoskeletal problems. Yet, the condition was recognized only recently.

  • You have access
    Is stress linked to heart disease?
    Fredric J. Pashkow, MD
    Cleveland Clinic Journal of Medicine February 1999, 66 (2) 75-77;

    Recent evidence confirms the popular folklore that mental stress has harmful effects on coronary health. Stress management programs are beneficial in coronary rehabilitation.

  • You have access
    New technology and new challenges for assisted reproduction
    Tommaso Falcone, MD
    Cleveland Clinic Journal of Medicine February 1999, 66 (2) 78-82;

    With advances in the science of reproduction come more options, and more ethical dilemmas.

  • You have access
    Deep brain stimulation reduces symptoms of Parkinson disease
    Erwin B. Montgomery, MD
    Cleveland Clinic Journal of Medicine January 1999, 66 (1) 9-11;

    When medications fail to control the symptoms of Parkinson disease, either surgery or a small implanted electrical device can help. With an illustration of how deep brain stimulation works.

  • You have access
    Idiopathic thrombocytopenic purpura: Guidance amid uncertainty
    Alan Lichtin, MD
    Cleveland Clinic Journal of Medicine November 1998, 65 (10) 510-514;

    A panel of experts has issued clinical guidelines for treating thrombocytopenic purpura, but points out that we lack solid evidence from randomized trials.

  • You have access
    The keyhole or the manhole? What internists need to know about minimally invasive CABG
    Joseph Sabik, MD
    Cleveland Clinic Journal of Medicine October 1998, 65 (9) 454-456;

    Thousands of patients have undergone minimally invasive coronary artery bypass surgery, but some have contraindications to it. With an illustration showing the two major minimally invasive techniques.

  • You have access
    The prostate cancer screening controversy in perspective
    Kenneth W. Vaughn, MD
    Cleveland Clinic Journal of Medicine October 1998, 65 (9) 459-462;

    The value of screening for prostate cancer is not yet proven, hut the magnitude of the problem argues for action.

  • You have access
    Ultrasound and alendronate: New tools for osteoporosis screening and treatment
    Richard P. Tonino, MD
    Cleveland Clinic Journal of Medicine September 1998, 65 (8) 398-401;

    Ultrasound should make osteoporosis easier to diagnose, and alendronate should make it easier to treat.

  • You have access
    New options for diagnosing and treating acromegaly
    Ariel L. Barkan, MD
    Cleveland Clinic Journal of Medicine July 1998, 65 (7) 343-349;

    Insulin-like growth factor 1 (IGF-1) is a more sensitive clinical marker of acromegaly than growth hormone. Two new somatostatin analogs are available for treatment. With an illustration explaining the growth hormone cascade.

Pages

  • Previous
  • Next
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 23

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire